learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
Search
forLearn
5 / 7 resultslearn Valproic acid
an anticonvulsant repurposed for hair loss via histone inhibition
learn Clascoterone
a novel topical treatment that inhibits DHT on androgen receptors
learn Tofacitinib
a JAK inhibitor for alopecia areata and other autoimmune conditions
learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
Research
5 / 1000+ results
research Perifollicular Pink Halo: A Potential Dermoscopic Marker of Inflammation in Central Centrifugal Cicatricial Alopecia
Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
research Recent Approaches of Antibody Therapeutics in Androgenetic Alopecia
Antibody treatments show promise for hair loss but need more research.
research Australasian Society for Dermatology Research Meeting, May 2006
The meeting highlighted the genetic basis of female pattern hair loss and various skin health insights.
research More About X-Linked Testicular Feminization of the Mouse as a Noninducible (is) Mutation of a Regulatory Locus: 5α-Androstan-3α-17β-Diol as the True Inducer of Kidney Alcohol Dehydrogenase and β-Glucuronidase
A specific metabolite, not a receptor protein, triggers the production of certain kidney enzymes, but this process is disrupted in mice with a mutation causing testicular feminization.
research Novel Investigational Drugs for Alopecia Areata and Future Perspectives
JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.
Community Join
5 / 1000+ resultscommunity Hope Medicine announces HMI-115 phase II clinical trial for androgenetic alopecia in China
Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.
community Hope Medicine HMI-115 got 28M$ investment
Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.
community Hope Medicine HMI-115 Phase 1 Success in Australia! 14 hairs/cm2 increase in hair growth.
The conversation discusses a new hair growth treatment that showed a 14 hairs/cm2 increase in a trial, with mixed opinions on its effectiveness and potential cost. Some users are hopeful about combining it with existing treatments like oral minoxidil for better results.
community Hope Medicine has a new CEO. Calling it now, he's probably going to axe HMI.
Hair loss discussion includes Minoxidil, finasteride, and RU58841 treatments. Hope Medicine has a new CEO, possibly leading to HMI's termination.
community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.